Yucang He
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yucang He has a total of 98 co-authors. Here are the top co-authors by number of shared publications:
Songyun Zhao
Department of Plastic Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
8 shared publicationsWanying Chen
Department of Plastic Surgery, First Affiliated Hospital of Wenzhou Medical University, Wenzhou City, People’s Republic of China
8 shared publicationsHao Dai
Department of Plastic Surgery, First Affiliated Hospital of Wenzhou Medical University, Wenzhou City, People’s Republic of China
6 shared publicationsJiaheng Xie
Department of Plastic Surgery, Xiangya Hospital, Central South University, Changsha, China
5 shared publicationsYanming Chen
Department of Plastic Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
5 shared publicationsLiqun Li
Department of Plastic Surgery The First Affiliated Hospital of Wenzhou Medical University Wenzhou China
4 shared publications
Latest Publications
- Open Access
- 9 November 2026
- Published by Springer Nature in Molecular Medicine
Single-cell and spatial multi-omics of keloids and hypertrophic scars: shared repair programmes and candidate multicellular niches
- 9 November 2026
- Published by Springer Nature in Molecular Medicine
Open AccessSingle-cell and spatial multi-omics of keloids and hypertrophic scars: shared repair programmes and candidate multicellular niches
- 22 October 2026
- Published by Wiley in The FASEB Journal
- Vol. 40 (20) , e72409
A Senescence‐Related Signature for Risk Stratification and Predicted Immunotherapy Response in Breast Cancer: Integrative Pathology and Multi‐Omics Analysis
Cellular senescence exerts context‐dependent effects on breast cancer progression and therapeutic response through dynamic interactions with the tumor microenvironment; however, its pathological manifestations, cellular organization, and clinical significance remain incompletely understood. In this study, we integrated whole‐slide pathology images, bulk transcriptomic profiles, single‐cell ribonucleic acid (RNA) sequencing, spatial transcriptomics, and clinical data to systematically characterize senescence‐associated features in breast cancer. Quantitative pathology and deep‐learning features were extracted from hematoxylin and eosin‐stained images, and a senescence‐related signature (SRS) was constructed using machine‐learning survival models. The SRS effectively stratified patients into distinct prognostic groups and showed consistent performance across the internally divided TCGA‐BRCA subsets, with high‐SRS patients exhibiting significantly poorer survival. Single‐cell analyses revealed that senescence activity was predominantly enriched in epithelial and endothelial cells, whereas fibroblasts acted as major signal‐sending populations and mediated enhanced collagen‐related communication with tumor cells. Low‐SRS tumors displayed greater immune‐cell infiltration, higher immune‐checkpoint expression, higher immunophenoscores, and more favorable Tumor Immune Dysfunction and Exclusion (TIDE)/immunophenoscore (IPS)‐based predicted response profiles, while also exhibiting distinct drug‐sensitivity profiles. Integrative pathological, transcriptomic, and spatial analyses further identified STARD10 as a senescence‐associated candidate enriched in tumor regions and spatially concordant with senescence‐marker expression at the spot level. Functional experiments showed that STARD10 knockdown reduced cellular metabolic activity in CCK‐8 assays and suppressed migration and invasion, attenuated senescence‐associated β‐galactosidase staining and senescence‐associated secretory phenotype (SASP)‐related cytokine expression, and suppressed tumor growth in vivo. Collectively, these findings establish an integrated pathology‐ and multi‐omics‐derived senescence‐related signature for prognostic stratification and characterization of TIDE/IPS‐based predicted immunotherapy‐response profiles in breast cancer, while identifying STARD10 as a candidate biomarker and a potential target for further mechanistic and therapeutic investigation.
- 22 October 2026
- Published by Wiley in The FASEB Journal
- Vol. 40 (20) , e72409
A Senescence‐Related Signature for Risk Stratification and Predicted Immunotherapy Response in Breast Cancer: Integrative Pathology and Multi‐Omics Analysis
Cellular senescence exerts context‐dependent effects on breast cancer progression and therapeutic response through dynamic interactions with the tumor microenvironment; however, its pathological manifestations, cellular organization, and clinical significance remain incompletely understood. In this study, we integrated whole‐slide pathology images, bulk transcriptomic profiles, single‐cell ribonucleic acid (RNA) sequencing, spatial transcriptomics, and clinical data to systematically characterize senescence‐associated features in breast cancer. Quantitative pathology and deep‐learning features were extracted from hematoxylin and eosin‐stained images, and a senescence‐related signature (SRS) was constructed using machine‐learning survival models. The SRS effectively stratified patients into distinct prognostic groups and showed consistent performance across the internally divided TCGA‐BRCA subsets, with high‐SRS patients exhibiting significantly poorer survival. Single‐cell analyses revealed that senescence activity was predominantly enriched in epithelial and endothelial cells, whereas fibroblasts acted as major signal‐sending populations and mediated enhanced collagen‐related communication with tumor cells. Low‐SRS tumors displayed greater immune‐cell infiltration, higher immune‐checkpoint expression, higher immunophenoscores, and more favorable Tumor Immune Dysfunction and Exclusion (TIDE)/immunophenoscore (IPS)‐based predicted response profiles, while also exhibiting distinct drug‐sensitivity profiles. Integrative pathological, transcriptomic, and spatial analyses further identified STARD10 as a senescence‐associated candidate enriched in tumor regions and spatially concordant with senescence‐marker expression at the spot level. Functional experiments showed that STARD10 knockdown reduced cellular metabolic activity in CCK‐8 assays and suppressed migration and invasion, attenuated senescence‐associated β‐galactosidase staining and senescence‐associated secretory phenotype (SASP)‐related cytokine expression, and suppressed tumor growth in vivo. Collectively, these findings establish an integrated pathology‐ and multi‐omics‐derived senescence‐related signature for prognostic stratification and characterization of TIDE/IPS‐based predicted immunotherapy‐response profiles in breast cancer, while identifying STARD10 as a candidate biomarker and a potential target for further mechanistic and therapeutic investigation.
- Open Access
- 15 October 2026
- Published by Springer Nature in Stem Cell Research & Therapy
Molecular mechanisms and regulation of adipose-derived stem cell differentiation into vascular endothelial cells
- 15 October 2026
- Published by Springer Nature in Stem Cell Research & Therapy
Open AccessMolecular mechanisms and regulation of adipose-derived stem cell differentiation into vascular endothelial cells
- Open Access
- 22 September 2026
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 32 (9) , e71167
ApoE4 as a Therapeutic Target in Epilepsy: From Pathogenic Mechanisms to Precision Medicine
Background: Epilepsy is a heterogeneous central nervous system disorder characterized by recurrent seizures and is frequently accompanied by cognitive and neuropsychiatric comorbidities. Although apolipoprotein E4 (ApoE4) is well established as a genetic risk factor in Alzheimer's disease, its role as a modifier of epilepsy susceptibility, progression, and therapeutic response remains incompletely understood. Objective: This review aims to summarize current evidence regarding the molecular mechanisms, clinical implications, and therapeutic potential of ApoE4 in epilepsy, with emphasis on its relevance to precision medicine. Methods: A narrative review was conducted by synthesizing preclinical and clinical studies investigating the relationship between ApoE4 and epilepsy, including mechanisms related to neuroinflammation, synaptic dysfunction, lipid metabolism, blood–brain barrier (BBB) integrity, clinical phenotypes, and targeted therapeutic strategies. Results: ApoE4 contributes to epileptogenesis through multiple interconnected pathways. It promotes neuroinflammatory responses by activating microglia and inflammatory signaling, disrupts synaptic plasticity through N‐methyl‐D‐aspartate receptor dysfunction and excitation‐inhibition imbalance, impairs lipid and energy metabolism leading to neuronal hyperexcitability, and compromises BBB integrity. Clinically, ApoE4 carriers show increased seizure susceptibility, accelerated cognitive decline, hippocampal atrophy, and variable responsiveness to antiseizure medications. Emerging therapeutic approaches include ApoE4 structural correction, modulation of metabolic and inflammatory pathways, and gene‐based interventions.
- 22 September 2026
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 32 (9) , e71167
Open AccessApoE4 as a Therapeutic Target in Epilepsy: From Pathogenic Mechanisms to Precision Medicine
Background: Epilepsy is a heterogeneous central nervous system disorder characterized by recurrent seizures and is frequently accompanied by cognitive and neuropsychiatric comorbidities. Although apolipoprotein E4 (ApoE4) is well established as a genetic risk factor in Alzheimer's disease, its role as a modifier of epilepsy susceptibility, progression, and therapeutic response remains incompletely understood. Objective: This review aims to summarize current evidence regarding the molecular mechanisms, clinical implications, and therapeutic potential of ApoE4 in epilepsy, with emphasis on its relevance to precision medicine. Methods: A narrative review was conducted by synthesizing preclinical and clinical studies investigating the relationship between ApoE4 and epilepsy, including mechanisms related to neuroinflammation, synaptic dysfunction, lipid metabolism, blood–brain barrier (BBB) integrity, clinical phenotypes, and targeted therapeutic strategies. Results: ApoE4 contributes to epileptogenesis through multiple interconnected pathways. It promotes neuroinflammatory responses by activating microglia and inflammatory signaling, disrupts synaptic plasticity through N‐methyl‐D‐aspartate receptor dysfunction and excitation‐inhibition imbalance, impairs lipid and energy metabolism leading to neuronal hyperexcitability, and compromises BBB integrity. Clinically, ApoE4 carriers show increased seizure susceptibility, accelerated cognitive decline, hippocampal atrophy, and variable responsiveness to antiseizure medications. Emerging therapeutic approaches include ApoE4 structural correction, modulation of metabolic and inflammatory pathways, and gene‐based interventions.
- 30 June 2026
- Published by Springer Nature in Stem Cell Reviews and Reports
- Vol. 22 (7) , 1-13
Targeted Strategies of Adipose Stem Cells for Metabolic Diseases: Mechanisms and Clinical Translation Challenges
Metabolic diseases, such as obesity, type 2 diabetes mellitus, non-alcoholic fatty liver disease, and atherosclerosis, represent a growing global health burden. Adipose-derived stem cells (ADSCs) have emerged as promising therapeutic agents due to their multipotency, paracrine activity, and potential for engineering targeted interventions. This review highlights recent advances in targeted ADSC strategies, focusing on their mechanisms, clinical applications, and translational challenges. Key targeted approaches include engineered exosomes for precise immunomodulation, surface-modified ADSCs for enhanced tissue homing, and biomaterial-based delivery systems for sustained and local release. Preclinical studies have demonstrated that these strategies can significantly improve glucose homeostasis, reduce hepatic steatosis, and alleviate chronic inflammation. However, clinical translation faces hurdles, including donor-dependent heterogeneity, a lack of standardized protocols, and insufficient long-term safety data. Future efforts should prioritize the development of precision-targeted ADSC therapies through genetic engineering, functionalized biomaterials, and rigorously controlled clinical trials to fully exploit their potential to treat metabolic diseases. Background Metabolic diseases are prevalent worldwide, with conditions such as metabolic dysfunction-associated steatotic liver disease(MASLD), obesity, type 2 diabetes mellitus, and atherosclerosis affecting hundreds of millions of individuals. Existing therapies struggle to address the root causes of these conditions, creating an urgent clinical need. ADSCs have gained attention as a research hotspot due to their multifunctionality; however, the literature indicates that their clinical translation faces obstacles, including cellular heterogeneity, the absence of standardized protocols, and unresolved safety concerns. This review aims to review and summarize the research progress on targeted ADSC strategies for metabolic diseases, clarify their mechanisms of action, review preclinical and clinical evidence, and provide directions to overcome translational bottlenecks.
- 30 June 2026
- Published by Springer Nature in Stem Cell Reviews and Reports
- Vol. 22 (7) , 1-13
Targeted Strategies of Adipose Stem Cells for Metabolic Diseases: Mechanisms and Clinical Translation Challenges
Metabolic diseases, such as obesity, type 2 diabetes mellitus, non-alcoholic fatty liver disease, and atherosclerosis, represent a growing global health burden. Adipose-derived stem cells (ADSCs) have emerged as promising therapeutic agents due to their multipotency, paracrine activity, and potential for engineering targeted interventions. This review highlights recent advances in targeted ADSC strategies, focusing on their mechanisms, clinical applications, and translational challenges. Key targeted approaches include engineered exosomes for precise immunomodulation, surface-modified ADSCs for enhanced tissue homing, and biomaterial-based delivery systems for sustained and local release. Preclinical studies have demonstrated that these strategies can significantly improve glucose homeostasis, reduce hepatic steatosis, and alleviate chronic inflammation. However, clinical translation faces hurdles, including donor-dependent heterogeneity, a lack of standardized protocols, and insufficient long-term safety data. Future efforts should prioritize the development of precision-targeted ADSC therapies through genetic engineering, functionalized biomaterials, and rigorously controlled clinical trials to fully exploit their potential to treat metabolic diseases. Background Metabolic diseases are prevalent worldwide, with conditions such as metabolic dysfunction-associated steatotic liver disease(MASLD), obesity, type 2 diabetes mellitus, and atherosclerosis affecting hundreds of millions of individuals. Existing therapies struggle to address the root causes of these conditions, creating an urgent clinical need. ADSCs have gained attention as a research hotspot due to their multifunctionality; however, the literature indicates that their clinical translation faces obstacles, including cellular heterogeneity, the absence of standardized protocols, and unresolved safety concerns. This review aims to review and summarize the research progress on targeted ADSC strategies for metabolic diseases, clarify their mechanisms of action, review preclinical and clinical evidence, and provide directions to overcome translational bottlenecks.
- Open Access
- 5 November 2025
- Published by Elsevier in Materials Today Bio
- Vol. 35, 102524
Multifunctional hydrogel sensors with dynamic covalent networks for machine learning-assisted Parkinson's disease diagnosis and encrypted human-computer interaction
- 5 November 2025
- Published by Elsevier in Materials Today Bio
- Vol. 35, 102524
Open AccessMultifunctional hydrogel sensors with dynamic covalent networks for machine learning-assisted Parkinson's disease diagnosis and encrypted human-computer interaction
- Open Access
- 30 October 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1691814
Adipose-derived stem cell exosomes suppress NLRP3-mediated neuronal pyroptosis to attenuate seizures in a kainic acid-induced temporal lobe epilepsy model
Background: Pyroptosis-mediated neuroinflammation represents a critical pathological mechanism in drug-resistant temporal lobe epilepsy (TLE), while Adipose-derived stem cell exosomes (ADSC-Exos) may target this process through NLRP3 inflammasome inhibition. Our study investigated the therapeutic effects of ADSC-Exos by mitigating NLRP3-driven pyroptosis in TLE. Methods: We isolated ADSC-Exos, the characteristics of which were confirmed. The Kainic acid-induced mouse TLE model were used to assess the in vivo effect of ADSC-Exos. To evaluate ADSC-Exos penetration, brain tissues were collected for fluorescence quantification. TUNEL and Nissl staining were used to evaluate hippocampal neuronal damage. Pyroptosis markers were detected by Western blot, qRT-PCR, and immunofluorescence. Bioinformatics analysis was performed to explore potential miRNAs in ADSC-Exos that might contribute to their therapeutic effects. Results: Intravenously injected ADSC-Exos efficiently crossed the blood-brain barrier, peaking in brain accumulation at 4 hours post-administration. Treatment with ADSC-Exos resulted in a 48.9% reduction in seizure duration (p<0.0001) and a 42% reduction in spontaneous recurrent seizure frequency (p<0.0001) in temporal lobe epilepsy. Furthermore, ADSC-Exos exhibited significant neuroprotection while suppressing key pyroptosis-related proteins, including NLRP3, Caspase-1, GSDMD, and IL-1β. Bioinformatics analysis further identified 16 candidate miRNAs in ADSC-Exos potentially mediating these therapeutic effects. Conclusions: ADSC-Exos exert neuroprotective effects in temporal lobe epilepsy in association with regulation of the NLRP3-associated pyroptosis pathway, thereby suppressing neuroinflammation and neuronal death, highlighting their potential therapeutic value.
- 30 October 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1691814
Open AccessAdipose-derived stem cell exosomes suppress NLRP3-mediated neuronal pyroptosis to attenuate seizures in a kainic acid-induced temporal lobe epilepsy model
Background: Pyroptosis-mediated neuroinflammation represents a critical pathological mechanism in drug-resistant temporal lobe epilepsy (TLE), while Adipose-derived stem cell exosomes (ADSC-Exos) may target this process through NLRP3 inflammasome inhibition. Our study investigated the therapeutic effects of ADSC-Exos by mitigating NLRP3-driven pyroptosis in TLE. Methods: We isolated ADSC-Exos, the characteristics of which were confirmed. The Kainic acid-induced mouse TLE model were used to assess the in vivo effect of ADSC-Exos. To evaluate ADSC-Exos penetration, brain tissues were collected for fluorescence quantification. TUNEL and Nissl staining were used to evaluate hippocampal neuronal damage. Pyroptosis markers were detected by Western blot, qRT-PCR, and immunofluorescence. Bioinformatics analysis was performed to explore potential miRNAs in ADSC-Exos that might contribute to their therapeutic effects. Results: Intravenously injected ADSC-Exos efficiently crossed the blood-brain barrier, peaking in brain accumulation at 4 hours post-administration. Treatment with ADSC-Exos resulted in a 48.9% reduction in seizure duration (p<0.0001) and a 42% reduction in spontaneous recurrent seizure frequency (p<0.0001) in temporal lobe epilepsy. Furthermore, ADSC-Exos exhibited significant neuroprotection while suppressing key pyroptosis-related proteins, including NLRP3, Caspase-1, GSDMD, and IL-1β. Bioinformatics analysis further identified 16 candidate miRNAs in ADSC-Exos potentially mediating these therapeutic effects. Conclusions: ADSC-Exos exert neuroprotective effects in temporal lobe epilepsy in association with regulation of the NLRP3-associated pyroptosis pathway, thereby suppressing neuroinflammation and neuronal death, highlighting their potential therapeutic value.
- 26 September 2025
- Published by Springer Nature in Apoptosis
- Vol. 30 (11-12) , 2963-2988
Integrating pathology genomics and single-cell genomics to identify lactate metabolism-related prognostic features and therapeutic strategies for melanoma
Cutaneous melanoma (SKCM) is highly malignant and prone to developing treatment resistance. Lactate metabolism in the tumor microenvironment (TME) plays a crucial role in SKCM progression, immune evasion, and therapy resistance. This study aimed to integrate multi-omics data to systematically characterize the molecular features of lactate metabolism in SKCM, construct an effective prognostic model, and explore potential therapeutic strategies. Quantitative pathological features were extracted using CellProfiler and combined with deep learning features obtained from a pre-trained ResNet50 convolutional neural network. Gene set variation analysis (GSVA) was used to calculate lactate metabolism scores and identify associated pathological features. Single-cell RNA sequencing was applied to assess lactate metabolic activity across different cell types. These data, together with spatial transcriptomics, genomic alterations, immune infiltration profiles, and immunotherapy response data, were integrated to construct a lactate metabolism signature (LMS) prognostic model (comprising 3 pathological features and 11 genes). The model was developed using 101 combinations of 10 machine learning algorithms. Furthermore, RAB32 knockdown experiments were performed to verify its effects on melanoma cell proliferation, migration, invasion, and metabolism. A total of 443 pathological imaging features significantly associated with lactate metabolism were identified. Single-cell analysis revealed that melanoma cells exhibited the highest lactate metabolic activity, with markedly enhanced intercellular communication in the high-metabolism group. The LMS model demonstrated excellent prognostic performance in both the TCGA training and validation cohorts. Patients in the high-LMS group had significantly shorter survival, showed immune evasion features, and exhibited activation of melanoma-related metabolic and signaling pathways (e.g., oxidative phosphorylation). In contrast, the low-LMS group had stronger immune infiltration and higher expression of immune checkpoint molecules. The key gene RAB32 was significantly correlated with all lactate metabolism-related pathological features, was highly expressed in the tumor core, and its high expression predicted poor prognosis. RAB32 knockdown markedly inhibited melanoma cell proliferation, migration, and invasion; reduced lactate production; suppressed the expression of glycolytic enzymes and lactate transporters; and decreased extracellular acidification rate (ECAR) and oxygen consumption rate (OCR). In addition, it significantly inhibited tumor growth in mouse xenograft models. This study developed a multi-omics-integrated prognostic model (LMS) based on lactate metabolism, providing a novel tool for risk stratification and therapeutic decision-making in SKCM patients. It also identified RAB32 as a central player in tumor metabolic reprogramming and invasiveness, with promising potential as a therapeutic target.
- 26 September 2025
- Published by Springer Nature in Apoptosis
- Vol. 30 (11-12) , 2963-2988
Integrating pathology genomics and single-cell genomics to identify lactate metabolism-related prognostic features and therapeutic strategies for melanoma
Cutaneous melanoma (SKCM) is highly malignant and prone to developing treatment resistance. Lactate metabolism in the tumor microenvironment (TME) plays a crucial role in SKCM progression, immune evasion, and therapy resistance. This study aimed to integrate multi-omics data to systematically characterize the molecular features of lactate metabolism in SKCM, construct an effective prognostic model, and explore potential therapeutic strategies. Quantitative pathological features were extracted using CellProfiler and combined with deep learning features obtained from a pre-trained ResNet50 convolutional neural network. Gene set variation analysis (GSVA) was used to calculate lactate metabolism scores and identify associated pathological features. Single-cell RNA sequencing was applied to assess lactate metabolic activity across different cell types. These data, together with spatial transcriptomics, genomic alterations, immune infiltration profiles, and immunotherapy response data, were integrated to construct a lactate metabolism signature (LMS) prognostic model (comprising 3 pathological features and 11 genes). The model was developed using 101 combinations of 10 machine learning algorithms. Furthermore, RAB32 knockdown experiments were performed to verify its effects on melanoma cell proliferation, migration, invasion, and metabolism. A total of 443 pathological imaging features significantly associated with lactate metabolism were identified. Single-cell analysis revealed that melanoma cells exhibited the highest lactate metabolic activity, with markedly enhanced intercellular communication in the high-metabolism group. The LMS model demonstrated excellent prognostic performance in both the TCGA training and validation cohorts. Patients in the high-LMS group had significantly shorter survival, showed immune evasion features, and exhibited activation of melanoma-related metabolic and signaling pathways (e.g., oxidative phosphorylation). In contrast, the low-LMS group had stronger immune infiltration and higher expression of immune checkpoint molecules. The key gene RAB32 was significantly correlated with all lactate metabolism-related pathological features, was highly expressed in the tumor core, and its high expression predicted poor prognosis. RAB32 knockdown markedly inhibited melanoma cell proliferation, migration, and invasion; reduced lactate production; suppressed the expression of glycolytic enzymes and lactate transporters; and decreased extracellular acidification rate (ECAR) and oxygen consumption rate (OCR). In addition, it significantly inhibited tumor growth in mouse xenograft models. This study developed a multi-omics-integrated prognostic model (LMS) based on lactate metabolism, providing a novel tool for risk stratification and therapeutic decision-making in SKCM patients. It also identified RAB32 as a central player in tumor metabolic reprogramming and invasiveness, with promising potential as a therapeutic target.
- Open Access
- 17 September 2025
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 146 (4) , 1074-1088.e5
A Metabolism-Driven Prognostic Model and PSMD14–SP1–GYS1 Axis Reveal Therapeutic Vulnerabilities in Melanoma
- 17 September 2025
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 146 (4) , 1074-1088.e5
Open AccessA Metabolism-Driven Prognostic Model and PSMD14–SP1–GYS1 Axis Reveal Therapeutic Vulnerabilities in Melanoma